Source: High Yields
  • Sugarbud Craft Growers Corp. (SUGR) has amended the terms of its public offering of convertible debenture units
  • Sugarbud has reduced the conversion price of the convertible debentures from $1.39 to $1.29 per common share
  • Each debenture unit will consist of one 12.0 per cent secured convertible debenture and 775 common share purchase warrants
  • The company has also increased the size of the offering to up to $3,000,000 in gross proceeds
  • Sugarbud is a craft cannabis company focused on the cultivation and production of cannabis products
  • Sugarbud Craft Growers Corp. (SUGR) opened trading at C$1.29 per share

Sugarbud Craft Growers Corp. (SUGR) has amended the terms of its recently announced public offering of convertible debenture units.

Sugarbud has reduced the conversion price of the convertible debentures from $1.39 to $1.29 per common share and lowered the exercise price of the share purchase warrants from $1.39 to $1.29 per warrant. 

Each debenture unit will consist of one 12.0 per cent secured convertible debenture and 775 common share purchase warrants.

The company has also increased the size of the offering to up to $3,000,000 in gross proceeds.

Each warrant will entitle the holder to purchase one common share for a period of 5 years following the closing of the offering.

Debenture holders may elect to exchange their debentures for 15.0 per cent non-convertible secured notes.

The debentures will mature 5 years from the closing of the offering.

Sugarbud is a craft cannabis company focused on the cultivation and production of cannabis products.

Sugarbud Craft Growers Corp. (SUGR) opened trading at C$1.29 per share.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.